329 related articles for article (PubMed ID: 30225582)
21. Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis.
Mo W; Ding Y; Zhao S; Zou D; Ding X
PLoS One; 2020; 15(11):e0241924. PubMed ID: 33170908
[TBL] [Abstract][Full Text] [Related]
22. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
23. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Lee JJ; Shen J
Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
[TBL] [Abstract][Full Text] [Related]
24. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
25. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
[TBL] [Abstract][Full Text] [Related]
26. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
27. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
28. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
[TBL] [Abstract][Full Text] [Related]
29. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
[TBL] [Abstract][Full Text] [Related]
30. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
31. Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.
Schaafsma E; Zhang B; Schaafsma M; Tong CY; Zhang L; Cheng C
Breast Cancer Res; 2021 Jul; 23(1):74. PubMed ID: 34274003
[TBL] [Abstract][Full Text] [Related]
32. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
[TBL] [Abstract][Full Text] [Related]
33. Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Dialani V; Gaur S; Mehta TS; Venkataraman S; Fein-Zachary V; Phillips J; Brook A; Slanetz PJ
Radiology; 2016 Aug; 280(2):370-8. PubMed ID: 26937802
[TBL] [Abstract][Full Text] [Related]
34. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
35. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Lewin R; Sulkes A; Shochat T; Tsoref D; Rizel S; Liebermann N; Hendler D; Neiman V; Ben-Aharon I; Friedman E; Paluch-Shimon S; Margel D; Kedar I; Yerushalmi R
Breast Cancer Res Treat; 2016 Jun; 157(3):511-6. PubMed ID: 27225387
[TBL] [Abstract][Full Text] [Related]
36. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
Felts JL; Zhu J; Han B; Smith SJ; Truica CI
Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
[TBL] [Abstract][Full Text] [Related]
37. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
38. Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours.
Bernhardt SM; Dasari P; Glynn DJ; Woolford L; Moldenhauer LM; Walsh D; Townsend AR; Price TJ; Ingman WV
BMC Cancer; 2021 Jun; 21(1):736. PubMed ID: 34174867
[TBL] [Abstract][Full Text] [Related]
39. Establishment of a novel CNV-related prognostic signature predicting prognosis in patients with breast cancer.
Hu W; Li M; Zhang Q; Liu C; Wang X; Li J; Qiu S; Li L
J Ovarian Res; 2021 Aug; 14(1):103. PubMed ID: 34364397
[TBL] [Abstract][Full Text] [Related]
40. An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
Tang J; Cui Q; Zhang D; Liao X; Zhu J; Wu G
J Cell Mol Med; 2019 Aug; 23(8):4980-4990. PubMed ID: 31124293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
